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genetic polymorphisms could affect the treatment response and might 
be used as genetic marker of tumor response after radiation therapy.
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Subsets of patients with non-small cell lung cancer (NSCLC) respond 
remarkably well to small molecule tyrosine kinase inhibitors (TKI) 
speciﬁc for epidermal growth factor receptor (EGFR) such as geﬁtinib 
or erlotinib. Those patients are typically of East Asian ethnicity, female 
gender, no history of smoking or those with adenocarcinoma. In 2004, 
it was found that NSCLC occurring in patients with above-mentioned 
characteristics frequently harbors activating mutations of the EGFR 
gene. Of note, EGFR mutation is a ﬁrst molecular alteration in NSCLC 
that is more frequent in never smoking patients. Our case-control study 
indicated that EGFR mutations occurred independent of smoking and 
apparent inverse relationship with smoking was due to dilution by 
tumors without EGFR mutations that increased with smoking history. 
In general, about 80% of NSCLCs with EGFR mutations respond to 
EGFR-TKIs, whereas some 10% of tumors without the mutations do 
so. Several investigators claim that EGFR gene copy number is more 
predictive of response or survival, although at least in our cohort, 
EGFR mutations were far better than copy number. In addition, various 
predictive markers have been reported to date. Those include expres-
sion of ligands for EGFR, change in other HER family genes including 
HER2 mutation or downstream molecules of EGFR pathway (e.g., 
KRAS mutation, AKT phosphorylation, PTEN expression, etc.). 
It is common for patients to show disease progression after presenting 
with an initial marked response to EGFR-TKIs. Secondary mutation 
occurring in exon 20 of the EGFR gene (T790M ) has been associated 
with the acquired resistance to EGFR-TKI. We were able to conﬁrm 
that 7/14 patients with acquired resistance after initial dramatic re-
sponse had T790M, but that no novel mutations were found. New class 
of TKIs that are able to overcome T790M are currently being devel-
oped. Very recently, Engelman et al. reported that ampliﬁcation of the 
MET gene is another mechanism of acquired resistance of EGFR-TKI 
through activation of HER3 signaling. It is known that some NSCLCs 
have T790M or MET ampliﬁcation even before EGFR-TKI therapy. 
Obviously, these NSCLC would require another treatment strategy.
Since all but one phase III trials have failed to show a survival advan-
tage of the treatment arm involving EGFR-TKIs, it appears mandatory 
to select patients by several of above-mentioned biomarkers. Through 
these efforts, it would be possible to individualize EGFR-TKI treatment 
for patients suffering from lung cancer.
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Worldwide, lung cancer is responsible for more than one million death 
per annum and is the leading cause of cancer mortality. Most patients 
with lung cancer are not cured and the overall 5-year survival rate is 
approximately 15%. Recent advances in the knowledge of cancer biol-
ogy led to the identiﬁcation of several potential molecular targets that 
play a key role in cancer development and progression. Selective tar-
geting of cancer cells based on their molecular phenotype can provide 
effective anti-cancer activity avoiding the commonly experienced side 
effects induced by chemotherapy. The new agents range from antibod-
ies that form complexes with antigens on the surface of the cancer cell 
to small molecules that have been engineered to block key enzymatic 
reaction. The interaction of the drug with its target inhibits pathways 
that are essential for cell proliferation or activates pathways that culmi-
nate in cancer cell apoptosis. So far, the dominant clinical trial strategy 
for patients with Non-Small-Cell Lung Cancer (NSCLC) has been to 
include a generic population of patients, with no selection based on 
biological criteria and, most importantly, with none or poor target as-
sessment. Although recent clinical trials in NSCLC have demonstrated 
survival improvement without a deﬁned biological endpoint, the hazard 
of continuing to perform clinical trials without any patient selection 
carries the risk of administering the wrong drug to the wrong patient 
and considering ineffective a drug that could dramatically improve the 
outcome of some patients, even if those are numerically small. 
The Epidermal Growth Factor Receptors (EGFRs) stand at the origin of 
a major signaling pathway involved in the growth of lung cancer. The 
EGFR superfamily includes four distinct closely related transmembrane 
receptors: EGFR/erbB-1, HER2/erbB-2, HER3/erbB-3, and HER4/
erbB-4. EGFR is normally found on the surface of epithelial cells and 
has been found to be commonly overexpressed in a variety of human 
malignancies. Different ligands can lead to EGFR activation and sub-
sequent signal transduction, including the epidermal growth factor, the 
transforming growth factor alpha and neuregulins. After ligand bind-
ing to the extracellular receptor domain, EGFR undergoes homo- or 
heterodimerization and autophosphorylation of its intracellular tyrosine 
kinase domain. These autophosphorylation events trigger a cascade of 
downstream signals, which ultimately result in an increase of cellular 
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motility, proliferation and invasion, and a block of apoptosis, contribut-
ing to cancer development and progression. 
Geﬁtinib (ZD 1839, Iressa™, AstraZeneca, UK) and erlotinib (OSI 
774, Tarceva™, Genentech, US) are orally active, selective EGFR 
Tyrosine Kinase Inhibitors (EGFR-TKIs) that demonstrated anti-tumor 
activity in a variety of human cancer cell lines overexpressing EGFR. 
The encouraging results observed in phase II studies and the survival 
improvement observed in phase III trials in certain subgroup of patients 
indicate that these drugs are particularly effective in individuals with 
particular clinical or biological characteristics. Several clinical features 
were found associated with increased response or survival to EGFR-
TKIs, including never smoking history, female gender, adenocarcinoma 
histology and Asian ethnicity. During the last three years, biological 
predictors for EGFR-TKI sensitivity have been discovered. In 2004, 
three groups have shown that mutations in the TK domain of EGFR 
were associated with response of NSCLC to geﬁtinib or erlotinib. 
These mutations were somatic and more frequently observed in patients 
with clinical features known to be associated with TKI sensitivity, such 
as female gender, adenocarcinoma histology, Asiatic ethnicity and 
never smoking history. Many types of mutations have been reported, 
but so far only four drug-sensitive mutations have been validated. The 
most common EGFR drug-sensitive mutations are exon 19 deletions 
and exon 21 L858R substitution, together accounting for about 85% of 
all EGFR mutations in NSCLC. Other less frequent EGFR mutations 
include substitutions in exon 18 (G719A/C) and 21 (L861Q). Several 
other EGFR gene mutations have been described but their role is not 
clear, and it is not possible to exclude that some of them are artefacts. 
Although several retrospective and prospective studies showed that 
patients with EGFR mutations, particularly individuals harbouring 
exon 19 deletion, respond to TKIs, the impact on survival is unclear 
because of the possible prognostic rather than predictive value of such 
mutations. Survival analysis of the largest trials with TKIs showed no 
survival beneﬁt for patients harbouring EGFR mutations receiving a 
TKI, suggesting a possible prognostic impact. In the randomized pla-
cebo-controlled trial comparing erlotinib to placebo (BR21), presence 
of EGFR mutations did not predict for a survival beneﬁt from the TKI 
therapy, even if mutation analysis was restricted to patients harbour-
ing the most frequent EGFR mutations (exon 19 deletion and exon 
21 L858R substitution). Since the ﬁrst reports, clearly emerged that a 
signiﬁcant fraction of patients with EGFR mutations (12%-84%) do 
not respond to TKIs, suggesting that other mechanisms are involved 
in TKI sensitivity. Four studies evaluated EGFR gene copy number 
by Fluorescence In Situ Hybridization (FISH). In the Italian study, 
individuals with EGFR high polysomy or gene ampliﬁcation (deﬁned 
as EGFR FISH positive) had a signiﬁcantly higher response rate, and a 
signiﬁcantly longer time to progression and survival than patients with 
no EGFR gene gain (deﬁned EGFR FISH negative). In the randomized 
placebo-controlled phase III study of erlotinib versus placebo, EGFR 
FISH positive patients treated with erlotinib had higher response rate 
and longer survival than EGFR FISH positive treated with placebo 
(HR 0.44, p=0.008), whereas there was no advantage determined by 
the drug in FISH negative patients. The randomized placebo-controlled 
phase III study of geﬁtinib versus placebo (ISEL) conﬁrmed the better 
outcome in terms of response rate and survival for EGFR FISH positive 
patients treated with geﬁtinib than EGFR FISH positive treated with 
placebo, with no survival difference in EGFR FISH negative irrespec-
tive of the treatment. In the SWOG S0126 trial, where patients with 
bronchiolo alveolar carcinoma (BAC) were treated with geﬁtinib 500 
mg/day, Hirsch et al. observed longer survival for EGFR FISH positive 
patients over those who had no gene gain (HR 2.02, p=0.042). More 
recently, the ONCOBELL trial, a prospective phase II study evaluating 
response rate in EGFR FISH positive or never smoker patients treated 
with geﬁtinib conﬁrmed that EGFR FISH testing is useful for patient 
selection. In this study, response rate was 68% in EGFR FISH positive 
and no response was observed in never smokers negative for EGFR 
FISH and mutation. Response and survival improvement observed 
in EGFR FISH positive patients indicate that TKI therapy should be 
offered to patients with such biological characteristic. Because gain 
in copy number of the EGFR gene was associated with survival, and 
because FISH is readily available clinical test, the EGFR FISH analysis 
represents an ideal test for selecting patients candidate to TKI therapy.
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Targeted therapies directed against epidermal growth factor recep-
tor (EGFR) are effective in a subset of non-small cell lung cancer 
(NSCLC) patients, however the survival advantage in unselected popu-
lations is relatively modest (1, 2). Numerous tissue and serum based 
markers have been proposed as predictors of survival and response 
beneﬁt from EGFR inhibitors. EGFR gene copy number and muta-
tion analyses are now being explored in prospective clinical studies in 
enriched populations. These assays are very promising, however costly 
and not widely available. In contrast, protein expression studies by 
immunohistochemistry are routinely performed in many laboratories 
for selection of breast cancer patients to hormonal therapy and HER2 
inhibitor trastuzumab. 
The value of EGFR protein expression as a predictor of sensitivity to 
EGFR inhibitors is debated. Depending on the analyzed cohort, stain-
ing protocol and cut-off point, EGFR protein positivity is observed in 
approximately 60% - 90% of patients. Analyses from phase II clinical 
studies with geﬁtinib concluded that EGFR protein expression is not 
associated with increased response rates or prolonged survival (3). 
Phase III clinical studies with erlotinib versus placebo in combination 
with chemotherapy followed by maintenance erlotinib/placebo did not 
show any association of outcome and EGFR protein expression (4, 5). 
It may be concluded from these studies that concurrent treatment with 
EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is equally 
ineffective in EGFR positive (EGFR+) and EGFR negative (EGFR-
) patients. Results of NSCLC monotherapy trials with geﬁtinib or 
erlotinib indicated that approximately 8 - 13% of EGFR+ as compared 
to 2-5% of EGFR- chemotherapy-pretreated patients respond to these 
agents. Moreover, some survival improvement was observed in EGFR+ 
patients in prospective monotherapy studies (BR.21 trial - hazard ratio 
[HR]: 0.68, 95% conﬁdence interval [CI]: 0.49 - 0.95, p=0.02; ISEL 
trial - HR: 0.77, 95% CI: 0.56 - 1.08, p=0.126) whereas no survival ad-
vantage was shown in EGFR- patients (6, 7). Detailed analysis of cut-
off points to deﬁne EGFR protein positivity based on BR.21 and ISEL 
trials with erlotinib and geﬁtinib, respectively, indicated that low cut-
off points (i.e. 10% of cells with positive staining of any intensity) were 
better discriminators of survival advantage than higher cut-off points 
(8, 9). Other single-arm studies indicated that EGFR protein expression 
is associated with outcome independently from other biologic features 
(10, 11). In a combined cohort of geﬁtinib treated patients, EGFR+ pa-
tients for both gene copy number and protein expression had a median 
survival of 21 months, patients with single positive test - 11 months and 
